Download PDF

1. Company Snapshot

1.a. Company Description

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer.Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal production; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension.


It also provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans.The company was incorporated in 1997 and is headquartered in Allerød, Denmark.

Show Full description

1.b. Last Insights on CHEMM

ChemoMetec A/S' recent performance was driven by strong revenue growth, increasing by 22% to DKK 495.6 million, and a 39% rise in EBITDA to DKK 258.0 million. The company's XcytoMatic platform garnered increased interest, leading to an upgrade in guidance for 2025/26, with revenue expected to reach DKK 565-580 million and EBITDA in the range of DKK 320-335 million. The launch of new XcytoMatic products proceeded as planned, contributing to the positive trend.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

How Investors May Respond To ChemoMetec (CPSE:CHEMM) Q1 Beat and Shift to Software-Centric Model

Nov -12

Source:

Card image cap

Is ChemoMetec (CPSE:CHEMM) Overvalued After Its Recent Surge? A Closer Look at Current Valuation

Nov -11

Source:

Card image cap

Notification of managers’ transactions

Nov -07

Source:

Card image cap

Growth in revenue and operating profit

Nov -06

Source:

Card image cap

Upgrade of guidance

Oct -28

Source:

Card image cap

Procedure of the Annual General Meeting

Oct -09

Source:

Card image cap

Exploring Three Undiscovered Gems In The European Market

Oct -02

Source:

Card image cap

Annual Report 2024/25 - Growing revenue and EBITDA

Sep -11

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.57%)

6. Segments

Instruments

Expected Growth: 12%

ChemoMetec A/S's 12% growth is driven by increasing demand for automated cell counting and analysis in life sciences, expansion into emerging markets, and strategic partnerships. Additionally, the company's focus on innovation, quality, and customer satisfaction has led to market share gains and repeat business. Furthermore, the growing need for efficient and accurate cell analysis in biotechnology, pharmaceutical, and research industries also contributes to the company's growth.

Consumables

Expected Growth: 14%

Strong demand for automated cell counting and analysis in life sciences, increasing adoption of single-cell analysis in cancer research, and growing need for efficient cell culture monitoring drive Consumables growth from ChemoMetec A/S, with a 14% growth rate.

Service

Expected Growth: 11%

ChemoMetec A/S's 11% growth is driven by increasing demand for automated cell counting and analysis in life science research, rising adoption of single-cell analysis in cancer research, and growing need for high-throughput screening in pharmaceutical industries, coupled with the company's expanding product portfolio and strategic partnerships.

Other

Expected Growth: 10%

ChemoMetec A/S's 10% growth in 'Other' segment is driven by increasing demand for automated cell counting and analysis solutions in biotechnology and pharmaceutical industries, coupled with expansion into new geographic markets and strategic partnerships. Additionally, the company's focus on innovation and R&D has led to the development of new products and services, further contributing to the segment's growth.

7. Detailed Products

NucleoCounter

Automated cell counters for accurate and efficient cell counting

NucleoView

Advanced image analysis software for cell counting and characterization

Via2-Cassette

Disposable cassettes for cell counting and analysis

Via2-NC

Automated cell counters for high-throughput cell counting and analysis

NucleoChem

Automated cell counters for cell counting and analysis in chemical and biochemical applications

8. ChemoMetec A/S's Porter Forces

Forces Ranking

Threat Of Substitutes

ChemoMetec A/S has a moderate threat of substitutes due to the availability of alternative products in the market.

Bargaining Power Of Customers

ChemoMetec A/S has a low bargaining power of customers due to the specialized nature of its products.

Bargaining Power Of Suppliers

ChemoMetec A/S has a moderate bargaining power of suppliers due to the availability of multiple suppliers in the market.

Threat Of New Entrants

ChemoMetec A/S has a high threat of new entrants due to the growing demand for cell counting and analysis solutions.

Intensity Of Rivalry

ChemoMetec A/S operates in a moderately competitive market with a few established players, leading to a medium intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1.33%
Debt Cost 10.25%
Equity Weight 98.67%
Equity Cost 10.25%
WACC 10.25%
Leverage 1.34%

11. Quality Control: ChemoMetec A/S passed 9 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
EL.En

A-Score: 5.7/10

Value: 5.6

Growth: 6.1

Quality: 7.6

Yield: 6.2

Momentum: 5.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
InMode

A-Score: 4.9/10

Value: 6.6

Growth: 7.0

Quality: 9.4

Yield: 0.0

Momentum: 3.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
ChemoMetec

A-Score: 4.8/10

Value: 0.0

Growth: 7.8

Quality: 9.4

Yield: 0.6

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Eckert & Ziegler

A-Score: 4.7/10

Value: 2.0

Growth: 7.1

Quality: 7.5

Yield: 1.2

Momentum: 7.5

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
CellaVision

A-Score: 3.5/10

Value: 1.3

Growth: 6.7

Quality: 8.0

Yield: 1.9

Momentum: 0.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Guerbet

A-Score: 2.7/10

Value: 7.8

Growth: 2.6

Quality: 2.0

Yield: 2.5

Momentum: 0.0

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

742.0$

Current Price

742$

Potential

-0.00%

Expected Cash-Flows